Since haplotype analysis can capture the cisacting causal variants that are potentially associated with disease risk and disease progression [15–17], we investigated the effect of 6 haplotypes of these SNPs in CYP19 on the clinical outcome of LN-negative, HR-positive early breast cancers. The gene discussed is CYP19A1; the disease is breast cancer.